ZYUS Life Sciences Corporation (Canada), a clinical-stage company listed on the TSXV under the ticker ZYUS, received US Patent No. 12,616,704 from the USPTO on May 5, 2026, covering a cannabichromene (CBC) formulation for pain management. The patent, held through the company’s wholly owned subsidiary ZYUS Life Sciences Inc. and based on International Patent Application No. PCT/CA2021/050430, covers CBC both as a monotherapy and within a fixed-dose cannabinoid combination, and represents the company’s second US patent in pain management. The grant extends intellectual property protection to a non-intoxicating cannabinoid approach targeting neuropathic pain, including peripheral neuropathies such as diabetic and cancer-related neuropathy, reinforcing the mechanistic rationale that CBC may modulate pain signaling through pathways distinct from opioid receptor engagement.
CBC is a phytocannabinoid that, unlike delta-9-tetrahydrocannabinol, does not produce intoxicating effects. The compound is understood to interact with transient receptor potential (TRP) channels, including TRPA1 and TRPV1, which are implicated in peripheral nociception and the transmission of pain signals in conditions such as diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. By acting on these channels rather than opioid receptors, CBC represents a mechanistic departure from both opioid analgesics and many existing non-opioid pharmacotherapies. The newly issued patent covers this approach and also supports ZYUS’ lead drug candidate, Trichomylin (CBC-containing fixed-dose cannabinoid combination in softgel capsule form), which is the subject of the company’s first US pain management patent.
The company states that investigational new drug (IND)-enabling studies for the second drug candidate covered under the new patent have been completed, positioning the asset for potential initiation of clinical trials in the US. ZYUS has indicated that Phase II clinical development of Trichomylin is ongoing, though specific clinical results for this cohort remain undisclosed. The patent also provides a basis for potential regulatory exclusivity for CBC, subject to determination by the US FDA at the time of any marketing authorization application.
Context and competitive landscape
The neuropathic pain treatment space contains a range of mechanistic approaches at varying stages of development, and the ZYUS Life Sciences patent enters a field where both established pharmacotherapies and novel pipeline assets are competing for the same patient populations.
Among direct mechanistic peers engaging non-opioid, non-gabapentinoid pathways, Vertex Pharmaceuticals (US) has advanced suzetrigine, a selective Nav1.8 sodium channel blocker, which received US FDA approval in January 2025 under the brand name Journavx (suzetrigine) for moderate-to-severe acute pain in adults. Vertex is also evaluating suzetrigine in neuropathic pain indications, including diabetic peripheral neuropathy, in ongoing clinical programs. The Nav1.8 mechanism targets peripheral sensory neurons involved in pain transmission, representing a channel-based approach that shares a peripheral focus with CBC’s proposed TRP channel activity, though the two molecules engage distinct molecular targets. Vertex’s asset is currently in Phase II evaluation for neuropathic pain indications, with specific trial identifiers not available in the source material provided.